Cytokinetics, Incorporated

Cytokinetics, Incorporated's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Cytokinetics, Incorporated has 138.76M shares outstanding.

As of June 30, 2026, Cytokinetics, Incorporated maintains a current ratio of 6.66, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -732.36, indicating conservative leverage, while an interest coverage ratio of -5.57 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -56.76, reflecting losses generated across the asset base. The company generates approximately 94,130.39 in revenue per employee across its workforce of 629.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated generated 59.23M in revenue and converted that into -782.52M in net income, yielding earnings per share of -6.29. EBITDA reached -608.65M, while operating income came in at -619.63M.

As of June 30, 2026, Cytokinetics, Incorporated holds 1.02B in cash and equivalents against 1.11B in total debt, resulting in a net debt position of 780.61M. Total book value stands at -151.85M, with working capital of 898.98M providing operational flexibility.

Cytokinetics, Incorporated produced -486.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -22.11M in capital expenditures, free cash flow totaled -508.30M - equivalent to -4.08 per share.

Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated posted a gross margin of -212.95, reflecting its pricing power and cost economics. The operating margin of -1,046.12 and net profit margin of -1,321.12 provide insight into operational efficiency.

Cytokinetics, Incorporated's most recent stock split took place on June 25, 2013 with a 6:1 split ratio.